

## Mavyret® (glecaprevir/pibrentasvir) - Label update

- On September 26, 2019, the <u>FDA announced</u> the approval of <u>AbbVie's Mavyret</u> (<u>glecaprevir/pibrentasvir</u>), for an 8-week duration for the treatment of adults and children ages 12 years and older or weighing at least 45 kg who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV.
  - This approval shortens the treatment duration from 12 weeks to 8 weeks in this patient population.
- Mavyret is also approved for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
- Mavyret is the first 8-week treatment approved for all treatment-naïve adult and certain pediatric
  patients with HCV genotypes 1 through 6 both without cirrhosis and with compensated cirrhosis.
- The approval of Mavyret for treatment duration of 8-weeks in this population was based on EXPEDITION-8, a single-arm, open-label study in 343 treatment-naïve patients with genotype 1, 2, 3, 4, 5 or 6 chronic HCV infection and compensated cirrhosis.
  - The overall sustained virologic response (SVR12) or cure rate was 98% (335/343).
- Mavyret carries a boxed warning for risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV.
- The recommended dose of Mavyret for all HCV patients is three tablets taken orally at the same time once daily with food (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
  - Refer to the Mavyret drug label for the recommended treatment duration based on the patient population.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.